Compare GNTX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNTX | PTCT |
|---|---|---|
| Founded | 1974 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.7B |
| IPO Year | 1995 | 2006 |
| Metric | GNTX | PTCT |
|---|---|---|
| Price | $24.08 | $73.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 17 |
| Target Price | $26.60 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 1.00 | 0.90 |
| Revenue | ★ $2,534,268,965.00 | $264,734,000.00 |
| Revenue This Year | $6.89 | N/A |
| Revenue Next Year | $4.58 | $17.70 |
| P/E Ratio | ★ $23.54 | $78.72 |
| Revenue Growth | 9.55 | ★ 36.19 |
| 52 Week Low | $20.48 | $43.18 |
| 52 Week High | $29.38 | $90.87 |
| Indicator | GNTX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 37.38 |
| Support Level | $22.50 | $68.16 |
| Resistance Level | $24.03 | $72.09 |
| Average True Range (ATR) | 0.63 | 3.11 |
| MACD | 0.03 | -0.99 |
| Stochastic Oscillator | 60.44 | 39.28 |
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.